BACKGROUND & AIMS: Indications for intravenous proton pump inhibitors (IV PPI) include upper gastrointestinal bleeding (UGIB) from peptic ulcer disease with high-risk stigmata and patients receiving nothing by mouth (NPO). The objectives were to assess the extent of errors in indications for IV PPI use and to determine whether multidisciplinary interventions could improve IV PPI use and costs. METHODS: Part 1: Patients prescribed IV PPI during a period of 4 months were divided into 2 settings, UGIB or non-UGIB. The setting-specific appropriateness of the IV PPI indication and dosing regimen was determined. Part 2: Patients prescribed IV PPI before and after multidisciplinary interventions (educating physicians, a computerized dose template, pharmacists altering IV PPI orders in non-UGIB patients who were not NPO, and recommending a GI consult when a continuous infusion was ordered) were studied. Incidence of prescribing errors, IV PPI costs, and potential confounders were compared. RESULTS: Part 1: Only 50% of UGIB (n = 145) patients received IV PPI for an appropriate indication. Both indication and dosing regimen were appropriate in 21%. In the non-UGIB group (n = 95), 33% were truly NPO; 51% had a correct dosing frequency. Part 2: The postintervention (n = 105) group (vs the preintervention group, n = 113) showed a significant absolute reduction in the degree of inappropriate indication in the UGIB (26%; 95% confidence interval [CI], 10%-42%; P < .0001) and in the non-UGIB (41%; 95% CI, 24%-58%; P < .0001) subgroups. However, a greater improvement in underspending than overspending meant that overall costs were unchanged. CONCLUSIONS: IV PPI was frequently prescribed inappropriately and incorrectly; simple maneuvers resulted in reductions in errors.
BACKGROUND & AIMS: Indications for intravenous proton pump inhibitors (IV PPI) include upper gastrointestinal bleeding (UGIB) from peptic ulcer disease with high-risk stigmata and patients receiving nothing by mouth (NPO). The objectives were to assess the extent of errors in indications for IV PPI use and to determine whether multidisciplinary interventions could improve IV PPI use and costs. METHODS: Part 1: Patients prescribed IV PPI during a period of 4 months were divided into 2 settings, UGIB or non-UGIB. The setting-specific appropriateness of the IV PPI indication and dosing regimen was determined. Part 2: Patients prescribed IV PPI before and after multidisciplinary interventions (educating physicians, a computerized dose template, pharmacists altering IV PPI orders in non-UGIB patients who were not NPO, and recommending a GI consult when a continuous infusion was ordered) were studied. Incidence of prescribing errors, IV PPI costs, and potential confounders were compared. RESULTS: Part 1: Only 50% of UGIB (n = 145) patients received IV PPI for an appropriate indication. Both indication and dosing regimen were appropriate in 21%. In the non-UGIB group (n = 95), 33% were truly NPO; 51% had a correct dosing frequency. Part 2: The postintervention (n = 105) group (vs the preintervention group, n = 113) showed a significant absolute reduction in the degree of inappropriate indication in the UGIB (26%; 95% confidence interval [CI], 10%-42%; P < .0001) and in the non-UGIB (41%; 95% CI, 24%-58%; P < .0001) subgroups. However, a greater improvement in underspending than overspending meant that overall costs were unchanged. CONCLUSIONS: IV PPI was frequently prescribed inappropriately and incorrectly; simple maneuvers resulted in reductions in errors.
Authors: Sean M Hayes; Suzanne Murray; Martin Dupuis; Martin Dawes; Ian A Hawes; Alan N Barkun Journal: Can J Gastroenterol Date: 2010-05 Impact factor: 3.522
Authors: Samuel Quan; Alexandra Frolkis; Kaylee Milne; Natalie Molodecky; Hong Yang; Elijah Dixon; Chad G Ball; Robert P Myers; Subrata Ghosh; Robert Hilsden; Sander Veldhuyzen van Zanten; Gilaad G Kaplan Journal: World J Gastroenterol Date: 2014-12-14 Impact factor: 5.742
Authors: Alan N Barkun; Mamatha Bhat; David Armstrong; Martin Dawes; Allan Donner; Robert Enns; Janet Martin; Paul Moayyedi; Joseph Romagnuolo; Larry Stitt Journal: CMAJ Date: 2013-01-14 Impact factor: 8.262
Authors: Wolfgang Schillinger; Nina Hörnes; Nils Teucher; Samuel Sossalla; Daniel Sehrt; Klaus Jung; Mark Hünlich; Bernhard Unsöld; Bianca Geiling; Giuliano Ramadori; Reinhard Hilgers; Harald Schwörer; Gerd Hasenfuss Journal: Clin Res Cardiol Date: 2009-03-20 Impact factor: 5.460